Compound as well as synthesis method and application thereof
By molecular modification of antibacterial peptide LL-37 and chemical modification of cordycepsin and paclitaxel, the compound 3'-dA-StLK-24-PTX with double-staple peptide structure was synthesized, solving the toxic side effects and insufficient stability of traditional anti-cancer drugs. The problem of this paper significantly improves the inhibitory rate of cancer cells and enhances the anti-tumor effect through inducing autophagy and apoptosis mechanisms.
Patent Information
- Application Number
- CN202410731434.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-06-13
- Filing Date
- 2024-06-06
- Publication Date
- 2024-11-22
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Traditional anti-cancer drugs have serious toxic and side effects, resulting in limited efficacy and insufficient stability and tumor suppressive activity. It is difficult for existing therapeutic strategies to effectively target cancer cells.
By molecularly modifying the antimicrobial peptide LL-37, chemically modifying cordycepsin and paclitaxel, the compound 3'-dA-StLK-24-PTX with a double-staple peptide structure is synthesized to enhance its stability and tumor suppressive activity, and Induce the expression of autophagy-related proteins to enhance anti-tumor effects.
The efficient inhibition of SW1990 human pancreatic cancer cells and ME-180 human cervical epidermal cancer cells was achieved, with the inhibition rate reaching 99.16% and 99.87%, and the anti-tumor effect was significantly improved by inducing autophagy and apoptosis mechanisms.
Smart Images

Figure CN118994322A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of cancer drug synthesis, and in particular to a compound and a synthesis method and application thereof. Background Art
[0002] Cancer is a major threat to human health. The toxic side effects of traditional anticancer drugs greatly limit their efficacy. It is particularly urgent to research and develop new anticancer drugs and treatment strategies. Combination therapy can greatly reduce the dosage of drugs, play a complementary role, and enhance the anticancer effect. Cancer is one of the malignant diseases faced by the world, and there is currently no effective treatment.
[0003] Cancer is a major disease that affects human health, and the research and development of anticancer drugs has always been a hot topic. Many small molecule compounds such as paclitaxel (PTX), cordycepin (Co) and antimicrobial peptides (AMP) have been used in the treatment of cancer, but PTX has certain cytotoxicity in clinical application, such as severe allergic reactions, neurotoxicity, hematological toxicity, etc., which limits the dosage of PTX; the active ingredient of cordycepin, 3'-deoxyadenosine (3'-dA), is easily hydrolyzed by adenosine deaminase (ADA) in the body, and only a very small amount of the drug is delivered to cancer cells to play a role; natural AMP also has the defect of unstable performance and is easily hydrolyzed by proteases and loses its activity, and the affinity of antimicrobial peptides for cancer cells is weaker than that of bacteria. The above-mentioned drawbacks have greatly limited the clinical application of these small molecule compounds, reflecting the difficult dilemma that the toxic side effects of many traditional anticancer drugs have become an important limiting factor that seriously affects their efficacy. The discovery of new anticancer drugs and treatment strategies with low toxicity and high efficiency is becoming increasingly urgent. Combination therapy is currently a relatively effective treatment method that can greatly reduce the dosage of drugs, play a complementary role, and enhance the anticancer efficacy, but it is limited to a simple mixture of several drugs.
[0004] Paclitaxel (PTX) is a commonly used chemotherapy drug for the treatment of cancer, but its safety and efficacy are low. Cordycepin (3'-dA) also has certain anti-cancer activity. Antimicrobial peptides (AMPs) also have anti-cancer activity after molecular modification into anti-cancer peptides, but they are easily hydrolyzed by proteases in cells and lose their activity. Therefore, the development of new anti-cancer drugs with good stability and strong anti-cancer activity is an urgent problem to be solved. Summary of the invention
[0005] In order to synthesize a novel anticancer drug with strong tumor suppressor activity, the present invention provides a cordycepin-bis-staple peptide-paclitaxel compound and a synthesis method and application thereof. The 3'-dA-StLK-24-PTX compound synthesized by the present invention has an inhibition rate on SW1990 human pancreatic cancer cells and ME-180 human cervical epidermal cancer cells, providing a new idea for the development of novel anticancer drugs, and can also induce the expression of autophagy-related protein LC3-Ⅱ and truncated fragments tATG5N and tBeclin-1C.
[0006] The first object of the present invention is to provide a compound, according to the structural characteristics of the antimicrobial peptide LL-37, the α-helical region, β-folded region, transmembrane structure, signal peptide, charge, hydrophobic region and hydrophilic region amino acids are molecularly modified to obtain a highly hydrophobic antimicrobial peptide LK-24 molecule, and the stapled peptide is modified and the amino acid is replaced again to obtain a double stapled peptide StLK-24;
[0007] 3'-dA and PTX are chemically modified respectively; the modified 3'-dA is connected to the amino end of StLK-24, and the modified PTX is connected to the carboxyl end of StLK-24 to obtain a compound.
[0008] Furthermore, the synthesis process of the double-stapled peptide StLK-24 is as follows: retaining the amino acids 13-36 of the antimicrobial peptide LL-37, replacing individual amino acids at the carboxyl end to improve hydrophobicity, obtaining the antimicrobial peptide LK-24 molecule, performing stapled peptide modification and amino acid replacement on LK-24, and obtaining the modified double-stapled peptide StLK-24.
[0009] Furthermore, StLK-24 was obtained by double-staple peptide modification of LK-24, and the specific steps are as follows:
[0010] ① Weighing and swelling of resin
[0011] Weigh 0.5 g of 2-CTC resin and add it to a peptide synthesis reaction tube. Add 5 mL of DCM to a 30×15 mm solid phase reaction tube to completely immerse the resin in the DCM solvent. Rinse the inner wall of the reaction tube with a DCM washing bottle to allow full contact with the solvent and swell for 10 minutes.
[0012] ②Preparation of Fmoc-CYS(Trt)-resin
[0013] Washing: After swelling is complete, add 5 ml of DMF and wash three times, 30 seconds each time.
[0014] Condensation: 0.15 mmol of Fmoc-CYS(Trt)-oh was dissolved in 30 ml of DCM, 0.5 mmol of DIEA was added, and the mixture was reacted for 2 h with nitrogen bubbling.
[0015] Washing: Drain the reaction solution, add 5 ml DMF and wash 4 times, 30 seconds each time. Drain after the 5th wash.
[0016] Capping: Prepare 3 ml of methanol: DIEA: DCM in a volume ratio of 1:1:2, add it into a drained solid phase reaction tube, and react with nitrogen bubbling for 30 minutes.
[0017] Washing: After the reaction is completed, the reaction solution is aspirated and 5 ml of DMF is added for washing 5 times, each time for 30 seconds.
[0018] ③ Preparation of Fmoc-Lys(Boc)-CYS(Trt)-resin
[0019] De-Fmoc: add 5 ml of 20% piperidine / DMF solution into the reaction tube and react with nitrogen bubbling for 20 min.
[0020] Washing: After deprotection, drain the resin and add 5 ml of DMF to wash 5 times, 30 seconds each time.
[0021] Detection: Use a long pipette to suck 10-20 resins into a test tube, add two drops of detection reagent A and two drops of detection reagent B respectively, and place in a 100℃ water bath for 30 seconds to allow the resin to develop color.
[0022] Condensation: 0.5 mmol Fmoc-Lys(Boc)-oh and 0.5 mmol HOBT were placed in a solid phase reaction tube, dissolved with 5 ml DMF, and then 0.5 mmol DIC was added, and nitrogen was bubbled for reaction for 1 hour.
[0023] Washing: After the reaction is completed, the reaction solution is aspirated and 5 ml of DMF is added for washing 5 times, each time for 30 seconds.
[0024] Detection: Use a long pipette to draw 10-20 resins into a test tube, add two drops of detection reagent A (2.5g ninhydrin + 50ml ethanol) and two drops of B (analytical grade pyridine) respectively, and place in a 100℃ water bath for 30s. The resin does not show color.
[0025] ④ Repeat step ③ and sequentially couple the remaining amino acids to obtain the following resin peptide
[0026] FMOC-S5-RQL-S5-KAKK-CYS-resin
[0027] ⑤ Peptide chain stapling cyclization
[0028] Grubbs catalyst was dissolved in DCM at a concentration of 7 mg / ml. The volume was 5 ml. The stapled peptide was obtained after catalytic reaction for 4 h, and then the synthesis was continued. In step ④, S5 is the cyclization site.
[0029] ⑥ Repeat step ③ and sequentially couple the remaining amino acids to obtain the following resin peptide
[0030] FMOC-LK-S5-RVW-S5-RVKKLLKRY-S5-RQL-S5-KAKK-CYS-resin
[0031] ⑦ Peptide chain stapling cyclization
[0032] Grubbs catalyst was dissolved in DCM at a concentration of 7 mg / ml. The volume was 5 ml and the double-stapled peptide was obtained after catalytic reaction for 4 h. Then, Fmoc removal was performed: 5 ml of 20% piperidine / DMF solution was added to the reaction tube and nitrogen was bubbled for 20 min.
[0033] Washing: After deprotection, drain the resin and add 5 ml of DMF to wash 5 times, 30 seconds each time.
[0034] Detection: Use a long pipette to suck 10-20 resins into a test tube, add two drops of detection reagent A and B respectively, and place in a 100℃ water bath for 30 seconds. The resin will develop color and obtain the (i,i+4) type double-stapled peptide StLK-24 (LKXRVWXRVKKLLKRYXRQLXKAKKC), where X is the stapled position.
[0035] The structural formula of StLK-24 is as follows:
[0036]
[0037] Furthermore, the compound is a cordycepin-bis-staple peptide-paclitaxel compound, abbreviated as 3'-dA-StLK-24-PTX, and its structural formula is:
[0038]
[0039] Furthermore, the compound is a cordycepin-bis-staple peptide-paclitaxel compound, abbreviated as 3'-dA-StLK-24-PTX, and its structural formula is:
[0040]
[0041] From the above compound structure, it can be seen that hydrogen bonds are formed between the two Xs, that is, the amino group of the amino acid (K) of the first X and the carbonyl group of the amino acid (K) of the second X form a hydrogen bond, thereby forming an α-helical stapled peptide structure; the amino group of the amino acid (W) of the third X and the carbonyl group of the amino acid (K) of the fourth X form a hydrogen bond, thereby forming an α-helical stapled peptide structure, and the four Xs can form a (i, i+4) type double stapled peptide structure. The specific reaction process can be expressed as:
[0042]
[0043] The second object of the present invention is to provide a method for synthesizing the above-mentioned compound. The synthesis process of the 3'-dA-StLK-24-PTX compound is specifically as follows:
[0044] S1, the antimicrobial peptide LL-37 is modified to obtain StLK-24, cysteine (Cys, C) is added to the carboxyl end of StLK-24 to form StLK-24-C, and the thiol group of cysteine reacts with the double bond in Mal on PTX-Mal to form StLK-24-PTX compound;
[0045] S2, condensing the 5'-COOH in the modified 3'-dA structure with the amino end of StLK-24 in the StLK-24-PTX compound to form a peptide bond, thereby preparing a 3'-dA-StLK-24-PTX compound.
[0046] Furthermore, in S1, the route for obtaining StLK-24-C by molecular modification of the antimicrobial peptide LK-24 is:
[0047]
[0048] The third object of the present invention is to provide the use of the above-mentioned compound in the preparation of anticancer drugs.
[0049] Furthermore, the anti-cancer activity refers to anti-cervical cancer and anti-pancreatic cancer.
[0050] Furthermore, the cordycepin-bistapeptide-paclitaxel compound can be used to prepare inducers of the autophagy-related protein LC3-Ⅱ and the truncated fragments tATG5N and tBeclin-1C.
[0051] Compared with the prior art, the present invention has the following beneficial effects:
[0052] 1. The present invention uses antimicrobial peptides, cordycepin (3'-dA) and paclitaxel as materials, combines bioinformatics technology, performs multiple molecular modifications on the antimicrobial peptide molecule LL-37, obtains the double-stapled peptide StLK-24, chemically modifies cordycepin and paclitaxel, and uses organic synthesis technology to synthesize the 3'-dA-StLK-24-PTX compound;
[0053] The present invention takes a unique approach, transforming the antimicrobial peptide molecule into a double-stapled peptide StLK-24 with anti-cancer activity, and then combining it with the tumor chemotherapy drug paclitaxel and chemically modified cordycepin to form a cordycepin-antimicrobial peptide-paclitaxel compound. MTT detected the inhibition rate of the compound on SW1990 human pancreatic cancer cells and ME-180 human cervical epidermal cancer cells, providing new ideas for the development of new anti-cancer drugs.
[0054] 2. The present invention modifies the structure of PTX and 3'-dA, further modifies the stapled peptide of LK-24 antimicrobial peptide, obtains a more stable (i, i+4) type double stapled peptide structure (Stapled LK-24, StLK-24), and uses StLK-24 as a skeleton, applies organic synthesis technology, designs a reaction route, connects the modified 3'-dA at the amino end of StLK-24, connects PTX at the carboxyl end, and synthesizes a compound 3'-dA-StLK-24-PTX containing three monomer components of cordycepin, paclitaxel and antimicrobial peptide. MTT experiments show that the inhibition rates of the compound 3'-dA-StLK-24-PTX at a concentration of 10 μM on the proliferation of SW1990 and Me180 cancer cells are 99.16% and 99.87%, respectively, which are significantly higher than the anticancer effects of other experimental groups; western Blotting showed that the 3'-dA-StLK-24-PTX compound could induce the expression of autophagy-related protein LC3-Ⅱ and truncated fragments tATG5N and tBeclin-1C, revealing the anti-tumor mechanism of the compound by inducing autophagy in cancer cells and apoptosis mediated by tATG5N and tBeclin-1C. The synthesis of this compound laid a foundation for the screening of new anti-tumor drugs. BRIEF DESCRIPTION OF THE DRAWINGS
[0055] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0056] Figure 1 A technical roadmap for the synthesis of 3'-dA-StLK-24-PTX compounds;
[0057] In the figure, A represents the modification process of cordycepin (3'-dA);
[0058] B represents the modification process of PTX to obtain paclitaxel-Mal;
[0059] C is the process of obtaining StLK-24-C through molecular modification of antimicrobial peptide LK-24;
[0060] D is the process of obtaining 3'-dA-StLK-24 by reacting modified 3'-dA with StLK-24-C;
[0061] E is the process of synthesizing 3'-dA-StLK-24 using 3'-dA-StLK-24 and PTX-Mal;
[0062] In the figure, a: Cordycepin (3'-dA); b: Paclitaxel (PTX); c: Maleimidopropionic acid (Mal); d: Paclitaxel-maleimidopropionic acid (PTX-Mal); e: antimicrobial peptide LK-24; f: modified double-stapled peptide StLK-24; g: Cordycepin-double-stapled peptide (3'-dA-StLK-24); h: Cordycepin-double-stapled peptide-paclitaxel (3'-dA-StLK-24-PTX).
[0063] Figure 2 This is the structure of the 3'-dA-StLK-24-PTX compound.
[0064] Figure 3 The antibacterial effect of 3'-dA-StLK-24-PTX compound on E. coli and S. aureus.
[0065] Figure 4 The MTT method was used to detect the anti-cancer activity of 3'-dA-StLK-24-PTX compound on SW1990 cancer cells.
[0066] Figure 5 The MTT method was used to detect the anti-cancer activity of 3'-dA-StLK-24-PTX compound on Me180 cancer cells.
[0067] Figure 6 The enzyme-labeled method was used to detect the hemolytic activity of 3'-dA-StLK-24-PTX compound on sheep erythrocytes.
[0068] Figure 7 Western blotting was used to detect the expression of LC3-Ⅱ, tBeclin-1C and tATG5N in SW1990 cancer cells;
[0069] In the figure, A shows the expression of LC3-Ⅱ in SW1990 cancer cells;
[0070] B is the expression of tBeclin-1C in SW1990 cancer cells;
[0071] C shows the expression of tATG5N in SW1990 cancer cells.
[0072] Figure 8 Western blotting was used to detect the expression of LC3-Ⅱ, tATG5N and tBeclin-1C in Me180 cancer cells;
[0073] In the figure, A shows the expression of LC3-Ⅱ in Me180 cancer cells;
[0074] B is the expression of tBeclin-1C in Me180 cancer cells;
[0075] C shows the expression of tATG5N in Me180 cancer cells. DETAILED DESCRIPTION
[0076] The specific embodiments of the present invention are described in detail below, but it should be understood that the protection scope of the present invention is not limited by the specific embodiments. Based on the embodiments in the present invention, all other embodiments obtained by ordinary technicians in this field without creative work belong to the scope of protection of the present invention. The experimental methods described in the embodiments of the present invention are conventional methods unless otherwise specified, and the materials, reagents, etc. used in the following embodiments can be obtained from commercial channels unless otherwise specified.
[0077] The present invention uses bioinformatics technology to perform molecular modification on the amino acids in the α-helix region, β-folding region, transmembrane structure, signal peptide, charge, hydrophobic region and hydrophilic region of the antimicrobial peptide LL-37 according to its structural characteristics, retains the amino acids at positions 13-36, replaces individual amino acids at the carboxyl end, improves hydrophobicity, and obtains an antimicrobial peptide LK-24 molecule composed of 24 amino acids. Inhibition zone experiments, MTT experiments and hemolysis experiments show that LK-24 has stronger antibacterial and anticancer activities and lower hemolysis than LL-37. In the first step, LK-24 was transformed into a double-stapled peptide StLK-24, and 3'-dA and PTX were chemically modified. The 5'-OH of 3'-dA was modified to 5'-COOH, and the 2'-OH of PTX was modified to PTX-Mal structure. Then, the 3'-dA-StLK-24-PTX compound was synthesized through organic synthesis technology. MTT was used to detect the inhibition rate of this compound on SW1990 human pancreatic cancer cells and ME-180 human cervical epidermal cancer cells, providing new ideas for the development of new anti-cancer drugs.
[0078] Example 1: Cordycepin-bis-staple peptide-paclitaxel compound and its synthesis method.
[0079] 1. Modification of 3'-dA, PTX and molecular engineering of antimicrobial peptides
[0080] 1. Modification of 3'-dA
[0081] OTBS was used to protect the 2'-hydroxyl group in the 3'-dA structure, and the 5'-hydroxyl group in the 3'-dA structure was modified to a 5'-carboxyl group, so as to facilitate condensation with the amino end of StLK-24 to form a peptide bond.
[0082] 2. Modification of PTX
[0083] The 2'-hydroxyl group in the PTX structure reacts with the carboxyl group in the maleimidopropionic acid (Mal) structure to form an ester (PTX-Mal).
[0084] 3. Molecular modification of antimicrobial peptides
[0085] According to literature reports, antimicrobial peptide database (http: / / aps.unmc.edu / AP / main.php) and bioinformatics analysis, the most representative antimicrobial peptide LL-37 molecule was screened out, and then according to the characteristics of LL-37 such as α-helix region, β-folded region, transmembrane structure, signal peptide, charge, hydrophobic region and hydrophilic region amino acids, LL-37 with an amino acid sequence as shown in SEQ ID NO.1 was molecularly modified to obtain an antimicrobial peptide LK-24 consisting of 24 amino acids (amino acid sequence as shown in SEQ ID NO.2). According to the reported stapled peptide design principle, LK-24 was again subjected to stapled peptide modification and amino acid replacement to obtain a modified double stapled peptide (Stapled Antimicrobial Peptides, StAMP) StLK-24 (shown in Table 1) with an amino acid sequence as shown in SEQ ID NO.3.
[0086] Table 1 Design of StLK-24
[0087]
[0088] Note: X in StLK-24 is the (i+4) double-stitching position.
[0089] The specific preparation steps of the double-stapled peptide StLK-24 are as follows:
[0090] ① Weighing and swelling of resin
[0091] Weigh 0.5 g of 2-CTC resin and add it to a peptide synthesis reaction tube. Add 5 mL of DCM to a 30×15 mm solid phase reaction tube to completely immerse the resin in the DCM solvent. Rinse the inner wall of the reaction tube with a DCM washing bottle to allow full contact with the solvent and swell for 10 minutes.
[0092] ②Preparation of Fmoc-CYS(Trt)-resin
[0093] Washing: After swelling is complete, add 5 ml of DMF and wash three times, 30 seconds each time.
[0094] Condensation: 0.15 mmol of Fmoc-CYS(Trt)-oh was dissolved in 30 ml of DCM, 0.5 mmol of DIEA was added, and the mixture was reacted for 2 h with nitrogen bubbling.
[0095] Washing: Drain the reaction solution, add 5 ml DMF and wash 4 times, 30 seconds each time. Drain after the 5th wash.
[0096] Capping: Prepare 3 ml of methanol: DIEA: DCM in a volume ratio of 1:1:2, add it into a drained solid phase reaction tube, and react with nitrogen bubbling for 30 minutes.
[0097] Washing: After the reaction is completed, the reaction solution is aspirated and 5 ml of DMF is added for washing 5 times, each time for 30 seconds.
[0098] ③ Preparation of Fmoc-Lys(Boc)-CYS(Trt)-resin
[0099] De-Fmoc: add 5 ml of 20% piperidine / DMF solution into the reaction tube and react with nitrogen bubbling for 20 min.
[0100] Washing: After deprotection, drain the resin and add 5 ml of DMF to wash 5 times, 30 seconds each time.
[0101] Detection: Use a long pipette to suck 10-20 resins into a test tube, add two drops of detection reagent A and two drops of detection reagent B respectively, and place in a 100℃ water bath for 30 seconds to allow the resin to develop color.
[0102] Condensation: 0.5 mmol Fmoc-Lys(Boc)-oh and 0.5 mmol HOBT were placed in a solid phase reaction tube, dissolved with 5 ml DMF, and then 0.5 mmol DIC was added, and nitrogen was bubbled for reaction for 1 hour.
[0103] Washing: After the reaction is completed, the reaction solution is aspirated and 5 ml of DMF is added for washing 5 times, each time for 30 seconds.
[0104] Detection: Use a long pipette to draw 10-20 resins into a test tube, add two drops of detection reagent A (2.5g ninhydrin + 50ml ethanol) and two drops of B (analytical grade pyridine) respectively, and place in a 100℃ water bath for 30s. The resin does not show color.
[0105] ④ Repeat step ③ and sequentially couple the remaining amino acids to obtain the following resin peptide
[0106] FMOC-S5-RQL-S5-KAKK-CYS-resin
[0107] ⑤ Peptide chain stapling cyclization
[0108] Grubbs catalyst was dissolved in DCM at a concentration of 7 mg / ml. The volume was 5 ml. The stapled peptide was obtained after catalytic reaction for 4 h, and then the synthesis was continued. In step ④, S5 is the cyclization site.
[0109] ⑥ Repeat step ③ and sequentially couple the remaining amino acids to obtain the following resin peptide
[0110] FMOC-LK-S5-RVW-S5-RVKKLLKRY-S5-RQL-S5-KAKK-CYS-resin
[0111] ⑦ Peptide chain stapling cyclization
[0112] Grubbs catalyst was dissolved in DCM at a concentration of 7 mg / ml. The volume was 5 ml and the double-stapled peptide was obtained after catalytic reaction for 4 h. Then, Fmoc removal was performed: 5 ml of 20% piperidine / DMF solution was added to the reaction tube and nitrogen was bubbled for 20 min.
[0113] Washing: After deprotection, drain the resin and add 5 ml of DMF to wash 5 times, 30 seconds each time.
[0114] Detection: Use a long pipette to suck 10-20 resins into a test tube, add two drops of detection reagent A and B respectively, and place in a 100℃ water bath for 30 seconds. The resin will develop color and obtain the (i,i+4) type double-stapled peptide StLK-24 (LKXRVWXRVKKLLKRYXRQLXKAKKC), where X is the stapled position.
[0115] The structural formula of StLK-24 is as follows:
[0116]
[0117] 2. Synthesis of 3'-dA-StLK-24-PTX Compound
[0118] 1. Synthesis of StLK-24-C-Mal-PTX (StLK-24-PTX) compound
[0119] First, cysteine (Cys, C) is added to the carboxyl end of StLK-24 to form StLK-24-C, and the thiol group of cysteine undergoes an addition reaction with the double bond in Mal on PTX-Mal to form the StLK-24-C-Mal-PTX (StLK-24-PTX) compound.
[0120] 2. Synthesis of 3'-dA-StLK-24-PTX compound
[0121] The 5'-OH of the 3'-dA structure is transformed into 5'-COOH (modification of 3'-dA), and the 5'-COOH in the modified 3'-dA structure is condensed with the amino end of StLK-24 in the StLK-24-PTX compound to form a peptide bond to prepare the 3'-dA-StLK-24-PTX compound. Figure 1 The structure of the finally synthesized 3'-dA-StLK-24-PTX compound is as follows Figure 2 . Its specific structural formula is as follows:
[0122]
[0123] From the above compound structure, it can be seen that hydrogen bonds are formed between the two Xs, that is, the amino group of the amino acid (K) of the first X and the carbonyl group of the amino acid (K) of the second X form a hydrogen bond, thereby forming an α-helical stapled peptide structure; the amino group of the amino acid (W) of the third X and the carbonyl group of the amino acid (K) of the fourth X form a hydrogen bond, thereby forming an α-helical stapled peptide structure, and the four Xs can form a (i, i+4) type double stapled peptide structure. The specific reaction process can be expressed as:
[0124]
[0125] 3. Synthesis of other compounds 3'-dA-LK-24 and 3'-dA-StLK-24
[0126] 1. The molecular structure of 3'-dA-LK-24 is:
[0127]
[0128] By analyzing the secondary structure, transmembrane hydrophobicity, C-terminal amphipathicity, charge offset, helix length, membrane protein topology, etc. of LL-37, the helical region, β-folding region, transmembrane structure, signal peptide, charge, hydrophobic region and hydrophilic region amino acids of the LL-37 antimicrobial peptide were changed to obtain a new antimicrobial peptide LK-24 after molecular modification. Then, using organic synthesis technology, the 5'-OH of the 3'-dA structural formula was transformed into 5'-COOH, which was condensed with the amino terminus of LK-24 to form a 3'-dA-LK-24 compound, which is the cordycepin-antimicrobial peptide conjugate.
[0129] 2. 3'-dA-StLK-24: The 5'-COOH in the modified 3'-dA structure is condensed with the amino end of StLK-24 to form a peptide bond to obtain 3'-dA-StLK-24.
[0130] Example 2: Application research of cordycepin-bis-staple peptide-paclitaxel compound.
[0131] 1. Study on the antibacterial and anticancer activities of cordycepin-bis-staple peptide-paclitaxel compound
[0132] 1. Study on the antibacterial activity of 3'-dA-StLK-24-PTX compound
[0133] Escherichia coli (ATCC8739) and Staphylococcus aureus (ATCC25923) were used as test strains to detect the antibacterial effects of anti-3'-dA-LK-24-PTX on Escherichia coli and Staphylococcus aureus.
[0134] 2. Anti-cancer activity of 3'-dA-StLK-24-PTX compound
[0135] Logarithmic phase SW1990 and Me180 cancer cells were collected, and 30 μL of 1640 (serum-free) medium and 10 μL of Actinomycin D were added in sequence, and then LK-24, 3'-dA, PTX, and 3'-dA-LK-24-PTX were added to make the final concentrations 100 μM, 80 μM, 60 μM, 40 μM, 20 μM, 10 μM, and 1 μM. A 10 μM concentration group was set for PTX, and the cell suspension concentration was adjusted to 1×10 6 / mL, add to 96-well plate, 100μL per well, four replicates for each experiment, incubate at 37℃, 5% CO2 for 48 hours, observe cell morphology under an inverted microscope, add 10μL WST-1 solution (5mg / mL, i.e. 0.5% WST-1) to each well, continue to culture for 4h, and directly detect OD by enzyme-linked immunosorbent assay 570 The absorbance of each well was measured at 37 nm, and the average value was taken to evaluate the anticancer effects of LK-24, StLK-24, 3'-dA, PTX, 3'-dA-LK-24, 3'-dA-StLK-24, and 3'-dA-LK-24-PTX.
[0136] 3. Hemolytic activity of 3'-dA-StLK-24-PTX compound
[0137] Fresh New Zealand white rabbit whole blood was collected, anticoagulated with heparin, centrifuged at 4℃3000r / min for 10min, and the precipitate was taken, washed with saline and resuspended at 8% (v / v). 100μL of red blood cell suspension was mixed with 100μL of 3'-dA-StLK-24-PTX solution of different concentrations (5, 10, 20, 50, 100, 200, 300, 400, 500μL / mL). The mixed system was placed in a 37℃ incubator, incubated for 1h, taken out and centrifuged at 4℃3000r / min for 10min, the supernatant was taken, and the absorbance at 570nm was measured using an enzyme marker. Positive control group: 0.1% TritionX-100 100μL; negative control group: 15μL water was added with saline to make up to 100μL. Similarly, the hemolytic activities of LK-24, StLK-24, 3'-dA, PTX, 3'-dA-LK-24, and 3'-dA-StLK-24 were studied.
[0138] The hemolysis percentage value was calculated according to the following formula: hemolysis (%) = (absorbance value of the test group - absorbance value of the negative control group) / (absorbance value of the positive control group - absorbance value of the negative control group) × 100%.
[0139] 4. 3'-dA-StLK-24-PTX compounds induce cancer cell responses to autophagy and apoptosis
[0140] SW1990 and Me180 cancer cells were treated with 3'-dA-StLK-24-PTX compounds, respectively. Cell pellets were collected every 8 hours, and total protein was extracted. After protein quantification, the contents of LC3-Ⅱ, truncated component tATG5N and tBeclin-1C in cancer cells were detected by western blotting to evaluate the response of cancer cells to 3'-dA-StLK-24-PTX compounds and LK-24, StLK-24, 3'-dA, PTX, 3'-dA-LK-24, and 3'-dA-StLK-24.
[0141] 2. Experimental Results
[0142] 1. 3'-dA-StLK-24-PTX compound has broad-spectrum antibacterial activity
[0143] Escherichia coli (E. coli, ATCC8739) and Staphylococcus aureus (S. aureus, ATCC25923) were used as test bacteria to detect the inhibition of 3'-dA-LK-24-PTX on the above two bacteria, and the inhibition curve was drawn. The inhibition curve showed that 0.65μM concentration of 3'-dA-StLK-24-PTX compound can kill more than 90% of Escherichia coli and Staphylococcus aureus, indicating that 3'-dA-StLK-24-PTX compound has extremely strong antibacterial activity ( Figure 3 ).
[0144] 2. 3'-dA-StLK-24-PTX compound has strong anticancer activity and low hemolysis
[0145] Through organic synthesis technology, we first coupled the antimicrobial peptide LK-24 modified by SAAP-148 with paclitaxel (PTX) and 3'-dA to obtain the 3'-dA-StLK-24-PTX compound.
[0146] The results of the MTT experiment showed that the inhibition rate of 10 μM concentration of 3'-dA-StLK-24-PTX compound on the proliferation of SW1990 and Me180 cancer cells reached 99.16% and 99.87%, respectively, which was higher than the anti-cancer effect of other experimental groups ( Figure 4 , Figure 5 ), the hemolytic assay showed that the hemolytic activity of the compound at a concentration of 128 μM on sheep erythrocytes was less than 20% (16.84%, Figure 6 ), showing that the compound has a strong inhibitory effect on cancer cells in vitro.
[0147] 3. 3'-dA-StLK-24-PTX compounds can induce autophagy and apoptosis in cancer cells
[0148] After SW1990 and Me180 cancer cells were treated with the compound, the levels of LC3-Ⅱ, truncated components tATG5N and tBeclin-1C in cancer cells were detected by western blotting. It was found that after treatment with the compound, the levels of LC3-Ⅱ, tATG5N and tBeclin-1C in cancer cells increased, indicating that the compound induced the response of cancer cells to autophagy and apoptosis ( Figure 7 , Figure 8 ).
[0149] Although the preferred embodiments of the present invention have been described, those skilled in the art may make other changes and modifications to these embodiments once they have learned the basic creative concept. Therefore, the appended claims are intended to be interpreted as including the preferred embodiments and all changes and modifications that fall within the scope of the present invention.
[0150] Obviously, those skilled in the art can make various changes and modifications to the present invention without departing from the spirit and scope of the present invention. Thus, if these modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalents, the present invention is also intended to include these modifications and variations.
Claims
1. A compound, characterized in that According to the structural characteristics of the antimicrobial peptide LL-37, the α-helical region, β-folded region, transmembrane structure, signal peptide, charge, hydrophobic region and hydrophilic region amino acids were molecularly modified to obtain the highly hydrophobic antimicrobial peptide LK-24 molecule, which was then further modified and amino acids were replaced to obtain the double-stapled peptide StLK-24. 3'-dA and PTX are chemically modified respectively; the modified 3'-dA is connected to the amino end of StLK-24, and the modified PTX is connected to the carboxyl end of StLK-24 to obtain the compound.
2. The compound according to claim 1, characterized in that The synthesis process of the double-stapled peptide StLK-24 is as follows: retaining the 13th to 36th amino acids of the antimicrobial peptide LL-37, replacing individual amino acids at the carboxyl end to improve hydrophobicity, obtaining the antimicrobial peptide LK-24 molecule, performing stapled peptide modification and amino acid replacement on LK-24, and obtaining the modified double-stapled peptide StLK-24.
3. The compound according to claim 2, characterized in that The compound is a cordycepin-bis-staple peptide-paclitaxel compound, abbreviated as 3'-dA-StLK-24-PTX, and its structural formula is:
4. A method for synthesizing the compound according to claim 3, characterized in that: The synthesis process of the 3'-dA-StLK-24-PTX compound is specifically as follows: S1, the antimicrobial peptide LL-37 is modified to obtain StLK-24, cysteine is added to the carboxyl end of StLK-24 to form StLK-24-C, and the thiol group of cysteine reacts with the double bond in Mal on PTX-Mal to form StLK-24-PTX compound; S2, condensing the 5'-COOH in the modified 3'-dA structure with the amino end of StLK-24 in the StLK-24-PTX compound to form a peptide bond, thereby preparing a 3'-dA-StLK-24-PTX compound.
5. The method for synthesizing the compound according to claim 4, characterized in that: In S1, the route for obtaining StLK-24-C by molecular modification of the antimicrobial peptide LK-24 is:
6. Use of the compound according to any one of claims 1 to 3 in the preparation of anticancer drugs.
7. Use of the compound according to claim 6 in the preparation of anticancer drugs, characterized in that: The anti-cancer effect refers to anti-cervical cancer and anti-pancreatic cancer.
8. The use of the cordycepin-bis-staple peptide-paclitaxel compound according to claim 6 in the preparation of anticancer drugs, characterized in that: The cordycepin-bistaplepeptide-paclitaxel compound can be used to prepare inducers of autophagy-related protein LC3-II and truncated fragments tATG5N and tBeclin-1C.
